More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.66B
EPS
1.09
P/E ratio
30.3
Price to sales
1.63
Dividend yield
--
Beta
0.971585
Previous close
$36.58
Today's open
$36.74
Day's range
$36.08 - $36.76
52 week range
$16.10 - $37.16
show more
CEO
Peter Anevski
Employees
856
Headquarters
New York, NY
Exchange
Nasdaq Global Select
Shares outstanding
73647334
Issue type
Common Stock
Healthcare
Healthcare Providers & Services
Progyny (PGNY) Is Up 3.85% in One Week: What You Should Know
Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research • 6 hours ago

Progyny: 3 Key Takeaways for Long-Term Investors
Progyny added 1.3 million covered lives for the 2027 plan year. Progyny achieved a near 100% pharmacy attach rate with new clients.
The Motley Fool • Nov 11, 2026

Fertility Treatment Leader Progyny Breaks Out Past Buy Point As Earnings Surge 113%
Progyny stock broke out past its latest buy point after the company's Q3 earnings surged 113% vs. year-ago period.
Investors Business Daily • Nov 9, 2026

Progyny Q3 Earnings Call Highlights
Progyny NASDAQ: PGNY raised the midpoint of its full-year 2026 guidance after reporting record third-quarter revenue and profitability and securing a record 1.3 million new covered lives during its latest selling season.
MarketBeat • Nov 5, 2026

Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Progyny, Inc. Announces Third Quarter 2026 Results
Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net IncomeSelling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention Raises Midpoint of Full Year Guidance Ranges NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2026 (“the third quarter of 2026”), as compared to the three-month period ended September 30, 2025 (“the third quarter of 2025” or “the prior year period”). “We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season, and over 85 new clients,” said Pete Anevski, Chief Executive Officer of Progyny.
GlobeNewsWire • Nov 4, 2026

Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates
Progyny (PGNY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.45 per share a year ago.
Zacks Investment Research • Nov 4, 2026

New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits
Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care
GlobeNewsWire • Oct 28, 2026

New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from a new clinical outcomes study showing significant improvements in menopause symptoms among members receiving care through its Menopause and Midlife program. The research found that more than 70% of members in the study experienced improvement in their menopause symptoms, with the greatest gains observed among those who received both personalized coaching and care from menopause-trained providers.
GlobeNewsWire • Oct 26, 2026

Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended September 30, 2026, after the close of the market on Wednesday, November 4, 2026.
GlobeNewsWire • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Progyny Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.